Condition: B-cell Non Hodgkin Lymphoma · Sponsor: Sanofi
This is an open-label, multiple ascending dose (MAD), phase 1 study in adult patients with relapsed or refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL). The purpose of the study is to identify possible optimal biological dosage(s) by assessing safety, tolerability, pharmacokinetics (PK), pharmacodynamics, clinical activity and immunogenicity of SAR448501/DR-0201. The study duration per participant will be approximately 3 years, including a screening period of up to 28 days, a treatment period of 52 weeks, a safety follow-up period of approximately 28 days and a long-term follow-up period of every 3 months until withdrawal of consent, participant death or study closure, whichever is sooner.
This description comes directly from the study's public registry record.
Trial Transparency email recommended (Toll free for US & Canada) · 800-633-1610 · Contact-US@sanofi.com
Always discuss trial participation with your own doctor first.
| Investigational Site Number : 001-203 | Camperdown, New South Wales, Australia | Recruiting |
| Investigational Site Number : 001-202 | Townsville, Queensland, Australia | Recruiting |
| Investigational Site Number : 001-205 | Adelaide, South Australia, Australia | Recruiting |
| Investigational Site Number : 001-204 | Melbourne, Victoria, Australia | Recruiting |
| Investigational Site Number : 001-201 | Perth, Western Australia, Australia | Recruiting |
| Investigational Site Number : 001-703 | Kamenitz, Serbia | Active Not Recruiting |
| Investigational Site Number : 001-601 | Singapore, Singapore | Recruiting |
| Investigational Site Number : 001-602 | Singapore, Singapore | Recruiting |
| Investigational Site Number : 001-401 | Busan, South Korea | Recruiting |
| Investigational Site Number : 001-403 | Busan, South Korea | Recruiting |
| Investigational Site Number : 001-404 | Goyang-si, South Korea | Recruiting |
| Investigational Site Number : 001-402 | Seoul, South Korea | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06392477